- Home
- ARVN vs SUJA Comparison
ARVN vs SUJA Comparison
Compare ARVN & SUJA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARVN | SUJA |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Beverages (Production/Distribution) |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 516.2M | 426.8M |
| IPO Year | 2018 | 2026 |
Fundamental Metrics
Financial Performance| Metric | ARVN | SUJA |
|---|---|---|
| Price | $9.29 | $9.14 |
| Analyst Decision | Buy | |
| Analyst Count | 19 | 0 |
| Target Price | ★ $15.05 | N/A |
| AVG Volume (30 Days) | 898.7K | ★ 903.2K |
| Earning Date | 05-04-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.84 | N/A |
| EPS | ★ 1.70 | N/A |
| Revenue | ★ $262,600,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $5.51 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.97 | $5.59 |
| 52 Week High | $14.22 | $11.93 |
Technical Indicators
Market Signals| Indicator | ARVN | SUJA |
|---|---|---|
| Relative Strength Index (RSI) | 58.81 | 58.73 |
| Support Level | $7.90 | $8.83 |
| Resistance Level | $9.65 | $11.34 |
| Average True Range (ATR) | 0.36 | 0.92 |
| MACD | 0.04 | 0.22 |
| Stochastic Oscillator | 73.65 | 86.48 |
Price Performance
Historical ComparisonAbout ARVN Arvinas Inc.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.